Roivant Sciences Ltd Ordinary Shares ROIV 深 滬
已收盤 10-17 16:00:00 美东时间
17.26
+0.150
+0.88%
華盛通- 最 高17.325
- 今 開17.11
- 成交量 879.37万股
- 最 低 16.88
- 昨 收 17.11
- 總市值 117.89亿
- 52周最高 17.325
- 市盈率 靜 --
- 換手率 1.29%
- 52周最低 8.73
- 委 比 -40.05%
- 總股本 6.83亿
- 歷史最高 17.325
- 量 比 1.44
- 振 幅 2.60%
- 歷史最低 2.52
- 每 手 1
- 風險率 0.89%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多美股盘后 | AST SPACEMOBILE涨13.08%，耐克涨3.61%
AST SPACEMOBILE涨13.08%；耐克涨3.61%；Acuity Brands涨2.04%
10-01 06:12
美股大行评级 | 上调！CrowdStrike、Lyft、MongoDB、Roivant等多只热门股获大行齐上调目标价
今日重点评级关注：Needham：上调爱美医疗评级至"买入"，目标价14美元；高盛：维持Roivant Sciences"买入"评级，目标价从20美元升至24美元
09-19 09:18
Roivant/Priovant's Experimental Drug Shows Promise In Rare Skin Disease Trial
Brepocitinib showed significant improvements in skin and muscle symptoms in dermatomyositis, with reduced steroid use and consistent safety results.
09-18 00:13
Lyft, Oruka Therapeutics, Roivant Sciences, Workday And Other Big Stocks Moving Higher On Wednesday
U.S. stocks were mixed, with the Dow Jones index gaining more than 200 points o...
09-17 22:12
Roivant and Priovant Announce Positive Phase 3 VALOR Study Results for Brepocitinib in 52-Week Placebo-Controlled Trial in Dermatomyositis (DM)
Roivant and Priovant announced positive results from the Phase 3 VALOR study of brepocitinib in dermatomyositis (DM). The study showed statistically significant improvements in skin and muscle disease measures, steroid-sparing effects, and rapid onset compared to placebo. At week 52, the 30 mg dose of brepocitinib achieved a mean Total Improvement Score (TIS) of 46.5 vs. 31.2 for placebo (p=0.0006). Over two-thirds of patients on 30 mg brepocitin...
09-17 11:00
Roivant Sciences Approves Proposals at Annual Meeting
An update from Roivant Sciences ( ($ROIV) ) is now available. On September 10, ...
09-12 05:29
Roivant Named on Fortune Media and Great Place To Work’s 2025 Best Workplaces in BioPharma List
<p>Roivant首次入选2025年Fortune最佳生物制药 workplaces名单，排名第28位（小中型企业类别）。该评选基于Great Place To Work的Trust Index™ Survey，分析了近4万员工的反馈。Roivant CEO Matt Gline表示，这一荣誉反映了团队致力于打造赋能、高绩效、人才驱动的企业文化。Fortune最佳生物制药 workplaces名单基于员工体验的六个关键问题，旨在选出为所有员工提供积极工作体验的公司。Roivant通过创建敏捷子公司“Vants”推动药物开发，并致力于改善患者生活。</p>
09-11 20:30
Roivant Sciences Announces Promising Study Results
Roivant Sciences ( ($ROIV) ) has provided an update. On September 3, 2025, Roiv...
09-04 01:57
Roivant Unveils Durability and Treatment-Free Six-month Remission Data with Potential to Change Treatment Paradigm for Uncontrolled Graves' Disease Patients
<p>Immunovant's batoclimab shows promising results for uncontrolled Graves' disease patients, with 80% achieving normal thyroid function after six months off treatment. Of these, 50% achieved anti-thyroid drug-free remission. Two registrational trials for IMVT-1402 are ongoing, with results expected in 2027. Immunovant will discuss these updates during an investor call on September 3, 2025.</p>
09-03 17:01
